Format

Send to

Choose Destination
Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):121-131. doi: 10.1080/14737167.2017.1298444. Epub 2017 Mar 17.

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.

Author information

1
a Pharmaceutical Outcomes Research and Policy Program , University of Washington , Seattle , WA , USA.
2
b US Value, Evidence and Outcomes, US Medical Affairs, GlaxoSmithKline , Durham , NC , USA.
3
c Personalized Medicine Asthma & Allergy Clinic Humanitas University, IRCCS-Humanitas Research Hospital , Rozzano-Milano , Italy.
4
d US Medical Affairs, Respiratory Therapeutic Area, GlaxoSmithKline , Durham , NC , USA.
5
e R&D, Respiratory Therapeutic Area Unit, GlaxoSmithKline , Durham , NC , USA.
6
f Health Economics, RTI-Health Solutions , Research Triangle Park , NC , USA.

Abstract

BACKGROUND:

Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo).

METHODS:

A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization.

RESULTS:

Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo.

CONCLUSIONS:

Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723-$840 per patient, differences were not statistically significant.

KEYWORDS:

Cost analysis; eosinophilic phenotype; exacerbation; mepolizumab; severe asthma

PMID:
28277854
DOI:
10.1080/14737167.2017.1298444
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center